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The ability of the hepatic mononuclear phagocytes to bind, ingest, and degrade 
circulating IgG immune complexes is recognized as a fundamental feature of the 
immune defense mechanisms (1).  This process involves specific interaction of 
IgG molecules in immune complexes with Fc receptors on the Kupffer cells (2- 
5). The general aspects of the Fc receptor structure and the secondary events 
associated with receptor-immune complex interactions are detailed in compre- 
hensive reviews (6,  7). 
Clinical and experimental studies have demonstrated that IgA immune com- 
plexes  (IgA-IC) Z play  an  important  role  in  certain  nephritides  (8-10).  The 
mechanisms, however,  that  govern  circulation  and  tissue  deposition  of IgA 
immune complexes remain largely unknown. 
A recent study demonstrated that soluble immune complexes ofdimeric (dIgA) 
and monomeric IgA (mIgA) behave similarly in circulation. The rate of removal 
of these complexes from circulation was directly related to the number of IgA 
molecules in the immune complexes and the liver was the primary organ involved 
in removal of circulating IgA immune complexes if four dIgA or eight mIgA 
molecules were present in the complex (11, 12). 
We have considered the possibility that the hepatic removal of IgA-IC from 
the circulation might be mediated by specific receptors. In the studies reported 
here, we used kinetic, morphologic, and binding specificity criteria, suggested 
by Silverstein et al. (7), to demonstrate in vivo the presence of specific receptors 
on Kupffer cells that bind and remove IgA-IC from circulation. 
Materials and Methods 
Preparation of Antibodies and Immune Complexes.  Mouse IgA anti-dinitrophenyl (DNP) 
was purified from the ascites of plasmacytoma MOPC-315 (obtained through the courtesy 
of Dr.  M.  Potter,  National  Institutes  of Health) as previously described  (9).  Covalently 
cross-linked  multimeric  IgA immune  complexes  were  prepared  with  bivalent  affinity- 
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labeling antigen,  bis-2,4-DNP pimelic ester (BDPE) (courtesy of Dr.  P.  Plotz,  NIH) by 
previously described procedures (I 1, 13). Complexes of varying lattice size were obtained 
by gel filtration on sequential 1.6 x  90-cm columns of Ultrogel AcA-22 and AcA-34 (LKB 
Instruments, Gaithersburg,  MD).  Fractions containing large or a mixture of large- and 
intermediate-latticed complexes eluted between 41  and 51% of the total column volume 
and were pooled and concentrated by negative pressure in a collodion sac (Schleicher & 
Schuell,  Keene,  NH).  These covalently linked polymers were stable in borate-buffered 
saline (BBS), pH 8.0, and had no tendency to change size upon concentration and storage. 
Purified fractions of dIgA were also pooled, concentrated, and used as control prepara- 
tions. 
Immune complexes containing mouse IgG were prepared with purified IgG anti-DNP 
and BDPE as describe above. The IgG anti-DNP was produced and purified as previously 
described (3). Purified immune complexes or dIgA were radiolabeled, 200 #Ci/mg, with 
carrier-free Na-~I (New England Nuclear, Boston, MA) using an iodine monochloride 
method (14). 
Preparation of Aggregated Proteins.  Heat-aggregated mouse IgG was prepared by slight 
modification of the method described by Dickler and Kunkel (15).  Purified mouse IgG 
(Cappel Laboratories, Cochranville, PA) was dissolved in phosphate-buffered saline (PBS), 
pH 7.4, to a concentration of 10 mg/ml, heated for 30 min at 63°C, and centrifuged at 
106,000 g for 60 rain.  The gelatinous pellet was redissolved and diluted  in PBS to the 
original concentration. The aggregated mouse IgG preparation was used only within 24 
h of preparation. 
Aggregated  human  serum  albumin  was  prepared  as  described  (5).  Human  serum 
albumin (Sigma Chemical Co., St Louis, MO) dissolved in BBS at a concentration of 30 
mg/ml was heated for 30 min at 79°C with continuous shaking.  Aggregates of human 
serum albumin were purified by gel chromatography on a Sepharose 4B column (Phar- 
macia Fine Chemicals, Piscataway, N  J). 
Animal  Experiments.  Female  2-3-too-old C57BL/6J  mice  (18-25  g)  were  obtained 
from The Jackson Laboratory, Bar Harbor, ME. Varying doses of radioiodinated immune 
complexes in 0.25 ml of BBS were injected into the tail vein. Blood samples, 20 #1, were 
obtained with heparinized micropipettes from the retroorbital venous plexus at different 
time intervals. Blood samples were expelled from the micropipettes into 0.5 ml of BBS in 
small glass tubes and an equal volume of 20% trichloroacetic acid (TCA) was added. After 
centrifugation  at  2,000  g  for  15  min,  the  TCA  pellet and  supernatant  were  counted 
separately in an automatic gamma counter. The values of TCA-precipitable radioactivity 
remaining in the blood were used to derive clearance curves; the first three data points 
were used to extrapolate the zero time value by linear regression analysis. The means and 
standard deviations were calculated for each time point, plotted, and analyzed by graphic 
peeling (16).  The elimination rate constant (K~) was derived from the slope of the curve 
(slope -- K~/2.303), which was calculated by a regression analysis program on a Hewlett- 
Packard 9845B computer-plotter. The half-life (t,/,) of circulating immune complexes was 
determined from the expression, t,/, =  0.693/Kel.  The clearance velocity of the injected 
IgA-IC was calculated with the formula, V -- 2.3026 SYo, where V is the clearance velocity, 
Y0 the Y intercept, and S the slope of the clearance curves at varying doses, as previously 
used for the study of immune complexes containing IgG (2). 
ln~munofluorescence Microscopy.  Mouse hepatic tissue was snap-frozen in n-hexane and 
cut with a cryostat into 4-~tm sections. The sections were air-dried, fixed in acetone for 
10 min at room temperature, washed twice with PBS, and then fluorescein-labeled goat 
antibodies to mouse IgA (Meloy Laboratories, Springfield, VA) were applied. Slides were 
incubated  for 30  rain  at  37°C  in  a  humid  chamber,  washed three  times in  PBS,  and 
mounted with Aqua-Mount (Lerner Laboratories, New Haven, CT). These preparations 
were examined with a Zeiss microscope equipped with a  Ploem-type vertical illuminator 
and a  100 W mercury light source. 
Light and Electron  Microscope Autoradiography.  The  125I-radiolabeled  IgA-IC, 7  t~Ci 
(28.7 gg) in BBS,  were administered intravenously. Mice were sacrificed 5 rain after the 
injection and liver slices (1-3 mm) were fixed overnight with  1.5%  glutaraldehyde in 0.1 RIFAI  AND  MANNIK  127 
M  sodium  cacodylate buffer,  pH  7.2.  After  1.5  h  postfixation  in  1%  OsO4,  the  liver 
specimens were dehydrated  in  graded ethanol  and  propylene oxide and embedded  in 
Epon  epoxy  resin.  1.0-#m  sections  were  coated  with  NTB-2  nuclear  tract  emulsion 
(Eastman Kodak, Rochester,  NY).  The coated slides were exposed for 2-6 wk at 4°C. 
The emulsion was then developed with D19 (Kodak) and fixed with 20% sodium thiosul- 
fate. The slides were stained with Toluidine Blue. 
The  flat  substrate  technique  described  by  Williams  (17)  was  selected  for  electron 
microscope autoradiography.  Ultrathin  sections,  60-90  nm,  were  stained  with  uranyl 
acetate and Reynold's citrate and coated with carbon.  Ilford nuclear research emulsion 
L4 (Polysciences, Inc., Warrington, PA) was applied to the slides. Emulsion-coated sections 
were exposed at 4 °C for 6-12 wk, developed with D 19 (Kodak), and transferred to grids. 
The preparations were examined with a Siemens 102 electron microscope (Siemens Corp., 
Iselin, N  J) operated at 60 kV. 
Light microscope autoradiographs were analyzed by counting grains over hepatocytes 
and nonparenchymal cells, then calculating the percentage of grains associated with each 
cell type. Electron micrographic prints, taken at random at a final magnification of 10,950, 
were analyzed for the area occupied by autoradiographic grains over each identified cell 
type, using an overlay transparency of a  calibrated grid. The results were expressed as 
the area of silver grains in tzm  2 per  100 #m  2 of cell area.  Ultrastructural characteristics 
were used to categorize the nonparenchymal cells.  Kupffer cells were identified by the 
following features: variable, stellate shapes; irregular plasma membrane with microvilli; 
numerous cytoplasmic dense bodies that are heterogeneous in density, shape, and diam- 
eter;  numerous,  large  cytoplasmic  vacuoles.  Endothelial  cells  were  identified  by  the 
streamlined shape of cell body and the thin, extended cytoplasm with numerous fenestra- 
tions. The infrequent fat-storing cells, localized usually within the space of Disse or in the 
recesses between the parenchymal cells,  were easily recognized by the characteristic fat 
droplets in the cytoplasm. 
Liver Perfusion Experiments.  A  previously described  system was  used  (18).  Briefly, 
under pentobarbital anesthesia, a long mid-line abdominal incision was made. The portal 
vein was isolated and a 22-gauge Angiocath (Deseret Co., Sandy, UT) was passed to the 
porta hepatis. The inferior vena cava was also cannulated with an Angiocath. The liver 
was flushed via the portal vein with Krebs-Henseleit buffer, pH 7.4, and then connected 
to the perfusion apparatus and perfused with oxygenated Krebs-Henseleit buffer warmed 
to 32°C, at a final flow rate of 3.5 mi/min. The outflow from the inferior vena cava was 
collected by a fraction collector at 1.8 ml/fraction. 
After the initial liver washout with plain perfusion fluid, a known amount of radioio- 
dinated test material in a  1-mt volume was introduced into the inflow perfusate, followed 
by  15  min  of continued  perfusion  with  oxygenated Krebs-Henseleit buffer.  After the 
perfusion, the liver was removed and the amount of radioactivity in the liver and the total 
outflow were measured. The total recovery of radioactivity in liver, inferior vena cava 
outflow, and the residual in the  injection tube was >95%.  Percent hepatic uptake was 
expressed as:  [Radioactivity in liver/(radioactivity in liver +  radioactivity in outflow)] × 
100. 
In the blocking studies, a large amount of the potential inhibitor was premixed with  1 
~g of the IgA-IC. The mixture was introduced into the perfusate and the outflow was 
collected and measured as described above. The effect of the test substance was expressed 
as the percent decrease of the hepatic uptake of radiolabeled IgA-IC. 
Results 
Clearance of IgA-IC by the Liver.  To characterize the clearance of multimeric 
IgA-IC, a  pooled  mixture  of large- and  intermediate-latticed  polymers of IgA 
were isolated by gel filtration. The injection of a small dose (1  tzg) of IgA-IC was 
used to characterize  the disappearance  of radioactivity from circulation  during 
a  60-min period.  At the end of this time, <10% of the injected radioactivity was 
TCA  precipitable.  The disappearance  curve consisted of two exponential  corn- 128  IgA  IMMUNE  COMPLEXES  RECEPTOR 
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FIGURE  I.  Clearance  curve and  hepatic  content  of IgA immune  complexes.  Mice  were 
injected with  1 #g of ]*sI-IgA-IC; the percent of radioactivity remaining in circulation (mean 
_  1 SD for three mice) is plotted against time after injection (0). The clearance curve consisted 
of two exponential components,  t,/,  =  1.1  min and  tv, =  60  min.  TCA-soluble radioactivity 
appeared in circulation with a  10-min lag period, as shown in the insert. The hepatic content 
of radioactivity is shown as percent of injected dose (l), determined in the blood-free liver. 
The radioactivity removed from circulation appeared principally in the liver. 
ponents,  determined  by graphic  peeling  in  conjunction  with  linear  regression 
analysis. The initial fast component had a mean t,/, of 1.1  min with 86.2 _  1.3% 
of the TCA-precipitable radioactivity eliminated from circulation at this half-life. 
The second component had a mean &, of 60 rain with 1.5.7 +  1.1% of the TCA- 
precipitable radioactivity removed from circulation at this half-life (Fig.  1). 
At 10 min,  18% of the administered dose was in the circulation while 77% of 
the amount  removed  from circulation  was localized  in  the  liver.  The  gradual 
decrease in hepatic content of radioactivity after 10 min was accompanied by an 
increase in TCA-soluble radioactivity in circulation  (insert,  Fig.  1).  The  radio- 
activity of intact  gallbladder,  monitored  between  10  and  60  min,  constituted 
only 0.34  _  0.14%  of the  injected  dose.  These  observations suggest  that  the 
hepatic uptake and degradation of the used IgA-IC occurred without a significant 
transport of radioactivity into the bile. 
Hepatic Localization oflgA-IC.  In previous studies (11), a liver cell separation 
technique  was used to determine  the cell type responsible for IgA-IC removal RIFAI  AND  MANNIK  129 
from circulation. Due to the elapse of 30-45 min between the administration of 
complexes and the final separation step in those studies, nonspecific cell to cell 
transfer of radioactivity could not be ruled out. Therefore, immunofluorescence 
microscopy was  used to detect the site of IgA-IC in the liver 5  min after  the 
intravenous injection. The IgA deposits were localized along the sinusoidal walls 
in a  granular  pattern consistent with the distribution of nonparenchymal cells 
(Fig.  2A).  The  IgA-IC  immunofluorescence pattern  was  very  similar  to  that 
detected with mouse IgG immune complexes (data not shown). Mice that received 
a larger dose of dIgA did not show any fluorescence in the liver (Fig. 2B). 
By light microscope autoradiography, performed on specimens obtained 5 min 
after  the administration of ~25I-IgA-IC,  94.4%  of the counted 2015  autoradi- 
ographic grains were associated with nonparenchymal cells. By electron micro- 
scope autoradiography Kupffer cells were identified as the predominant nonpa- 
renchymal cells associated  with the autoradiographic grains.  The results were 
expressed as the area of autoradiographic grains in ~tm  ~ per 100 t~m  2 of cell area. 
This value  was  9.6  for  Kupffer  cells,  1.1  for  endothelial  cells,  and  0.18  for 
hepatocytes. All identified Kupffer cells were heavily labeled (Fig.  3), whereas 
75%  of the  identified endothelial  cells contained no autoradiographic  grains. 
Furthermore,  the endothelial cells with autoradiographic grains were in close 
proximity to Kupffer cells and therefore the possibility remains that these grains 
were caused by ~25I in adjacent Kupffer cells. 
Effect of Increasing Dose on Disappearance Kinetics of lgA-IC.  If the removal of 
IgA-IC from circulation is mediated by a receptor system, it should be saturable 
with higher doses of the complexes. When the concentration of large-latticed 
IgA-IC  was  progressively  increased,  from  28  to  560  /zg  by  the  addition  of 
unlabeled IgA-IC to 2 #g ~I-IgA-IC,  the elimination rate was decreased from 
0.99 to 0.12, respectively (Fig. 4). The data from these experiments were used 
to calculate the clearance velocity of each dose of injected IgA-IC and plotted 
against  the  injected  dose.  The  clearance  velocity initially  increased  with  the 
injected dose and then plateaued at the level of 21  /~g/ml per minute (Fig. 5). 
These results are consistent with a saturable receptor-like process. 
Specificity of IgA-IC Clearance.  To determine whether saturation was specific 
for  the  IgA-IC  under  study,  various  potential  receptor  blocking agents  were 
injected simultaneously with  2  /zg of IgA-IC (Fig.  6).  A  large dose (2  rag)  of 
aggregated mouse IgG that effectively inhibits the clearance and hepatic uptake 
of IgG immune complexes (5,  19)  had  no effect on  the clearance or hepatic 
uptake of IgA-IC.  Similarly, 2  mg of microaggregated human serum albumin 
failed to influence the disappearance pattern and hepatic uptake of IgA-IC. In 
contrast, the simultaneous injection of 0.5 mg unlabeled IgA-IC with 2/~g ~I- 
IgA-IC increased the tv, from 1.1 to 12.1 min (Fig. 6). To exclude the possibility 
that a secretory component on the surface of hepatocytes might act as a receptor 
for  IgA-IC,  2  mg of dIgA,  which combines avidly with secretory  component 
(20), was administered simultaneously with 1 ~g of IgA-IC. No inhibitory effect 
was observed with free dIgA. These results suggest that saturation was specific 
for IgA and occurred when these antibody molecules are polymerized in immune 
complexes. 
Studies in the Perfused Mouse Liver.  The potential contribution of complement A
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FIGURE 3.  Electron  microscope  autoradiograph of mouse liver 5 min after injection of l~5I- 
lgA-IC. Dense collections of autoradiographic grains are associated with a Kupffer cell (K) 
and not with hepatocytes (H). The tissue was examined 6 wk after the coating with nuclear 
emulsion. × 7,070. 
components or other serum proteins to IgA-IC clearance could not be ruled out 
by in vivo studies.  For this reason studies were done with mouse liver perfused 
with a buffer, thus avoiding the presence of serum proteins. 
When a normal liver was perfused with 2 #g of dIgA, <3% hepatic uptake was 
observed  in a  single passage (Fig.  7).  In contrast, a  significant amount, 43.5  + 
4.9%, of large-latticed IgA-IC in Krebs-Henseleit buffer was removed. Virtually 
identical results were  obtained with  IgA-IC preincubated  for  30  min at  37°C 
with  heat-inactivated or  fresh  mouse  serum  before addition  to  the  perfusate. 
Thus, neither complement nor any other serum proteins contributed to hepatic 
removal of the tested IgA-IC. 
This  perfusion  system  was  also  used  to  test  the  effect of large  amounts  of 
different agents on the hepatic binding of a  trace dose of IgA-IC. Fucose is the 
terminal sugar reisude added to MOPC-315 IgA prior to secretion (21). To rule 
out the involvement of the fucose receptor on hepatocytes (22) in uptake of IgA- 
IC, 6 mg of fucoidin was perfused simultaneously with 1 #g ~sI-IgA-IC. Fucoidin 
did not alter the hepatic uptake of IgA-IC.  Similarly, 2  nag aggregated  mouse 
IgG, 2  mg aggregated human serum albumin, and 5  mg purified dIgA did not 
influence the  uptake of IgA-IC.  In  contrast,  1 mg of unlabeled IgA-IC caused 
an  88%  decrease  in  hepatic  uptake  of the  radiolabeled  IgA-IC.  These  results 132  IgA  IMMUNE  COMPLEXES  RECEPTOR 
50O 
100 
t- 
O 
.E  | 
~  10 
I  I-  !  I  I  I  I  I  I  I 
0  2  4  6  8  10 
Time in rain 
FIGURE 4.  Clearance curves of increasing doses of IgA-IC. The concentration (t~g/ml) of 
IgA-IC remaining in circulation was plotted against time during the initial rapid removal of 
injected complexes. Mice were given IgA-1C containing 2 tzg of l~sI-IgA-IC with increasing 
amounts of unlabeled lgA-IC with the same lattice. The gg/ml remaining were calculated 
from the radioactivity in 20 tA of blood and the specific activities of each preparation. The Ke~ 
was 0.99, 0.30, 0.19, and 0,12 for 28,  140, 280, and 560/~g of IgA-IC, respectively. Each 
point represents the observed mean value of three mice in each experiment. 
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FIGURE 5.  Effect  of increased doses of injected IgA-IC on the  initial clearance of these 
complexes. The clearance velocity (#g/ml-min  -I) was calculated using the data presented in 
Fig. 3. With the higher doses the clearance velocity reached a maximum, indicating a saturable 
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FIGURE 6.  Clearance of 2 t~g of 12SI-lgA immune complexes administered simultaneously 
with a 2 mg dose of heat-aggregated mouse lgG (O), aggregated human serum albumin (O), 
and purified dlgA (A). The clearance of l~5I-IgA-1C was inhibited only by 0.5 mg unlabeled 
IgA-IC (I). The dotted area represents the clearance of the test dose of 1~5I-IgA-IC (mean .4- 
SD). Each point represents the mean value of three mice. 
agreed well with the in vivo data and confirmed the specificity of the receptor 
for IgA-IC. 
Discussion 
The presented data permit a conclusion that distinct receptors exist on mouse 
Kupffer cells for the removal of circulating IgA in immune complexes. First, the 
clearance  of a  small  dose of radiolabeled  mouse  IgA  immune  complexes was 
rapid  and  it progressively decreased by the addition  of increasing  amounts  of 
identical,  unlabeled  IgA immune complexes (Fig.  4).  The clearance velocity of 
the IgA immune complexes increased with the dose of injected complexes and 
approached  a  maximum  value with  the  highest  doses (Fig.  5).  Second,  5  rain 
after  the  injection  of the  IgA  immune  complexes,  they  were  associated  by 
immunofluorescence and light microscope autoradiography with nonparenchy- 
real cells in the  liver.  Electron  microscope autoradiography  disclosed that  the 
radioactivity was predominantly within Kupffer cells. Third, the rapid clearance 
from circulation  of the test dose of IgA immune complexes was slowed by the 
unlabeled IgA immune complexes and not by IgG immune complexes or aggre- 
gated human serum albumin (Fig. 6). Thus, the criteria proposed by Silverstein 
et al.  (7)  for  the  existence  of specific receptors  for  the  uptake  of circulating 
materials were fully met. As previously documented, the rapid hepatic uptake of 
mouse  IgA  immune  complexes occurred  when  eight  or  more  IgA  molecules 134 
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FIGURE 7.  Recovery of radioactivity from the inferior vena cava after perfusion of the liver 
with  I  ttg of z~sI-IgA-IC  or ]~Sl dIgA in Krebs-Henseleit buffer. The cumulative percent of 
infused radioactivity was  calculated after the addition  of each successive  1.8-ml fraction of 
hepatic outflow. Less than  3% of the injected dlgA (O) was removed by the liver, but 43% of 
the IgA-IC (&) was removed in a single passage through the liver. 
were present in the complexes (1 I). This minimum could be achieved either by 
eight monomeric IgA molecules or by four dimeric IgA molecules. Thus,  the 
IgA-specific receptor on  mouse Kupffer cells does not distinguish  monomeric 
and dimeric IgA molecules. 
Several other points need to be considered in view of the presented data. The 
role of the secretory component on rat hepatocytes in hepato-biliary transport 
of polymeric IgA  is  well established  in  rats  (23-25).  Three  lines of evidence 
ruled out the participation of secretory component as a receptor for large-latticed 
lgA-IC in our studies. First, the amount of radioactivity detected in the bile at 
different intervals was extremely low, <0.5% of the injected dose. Second, large 
amounts of native dlgA failed to influence the IgA-IC clearance pattern (Fig. 6) 
or  hepatic  uptake  in  liver  perfusion  studies.  Third,  morphological  evidence 
showed uptake of IgA-IC by Kupffer cells.  The variance of these results with 
studies in rats is of interest but not unique, since morphological and functional 
studies in humans (26, 27) and other species (28) showed little or no hepatobiliary 
transport of polymeric IgA. 
In vitro experiments with isolated rat hepatocytes have suggested that recog- RIFAI AND MANNIK  135 
nition of a galactose or N-acetyl-galactosamine on polymeric IgA by a receptor 
on  hepatocytes may mediate  uptake  of IgA  (29,  30).  Such a  mechanism for 
removal of IgA-IC in mice appears unlikely since in the presented data native 
dIgA  did  not  affect the clearance or  hepatic  uptake  of IgA-IC.  In  addition, 
fucoidin, a blocker of fucose receptor on hepatocytes, failed to influence hepatic 
uptake  of complexes containing  IgA  derived from  MOPC-315.  As  indicated 
above, this IgA possesses fucose as terminal sugar residue on the oligosaccharide 
chain. Furthermore, Brown et al. (31) showed that galactose or mannose receptor 
blockers  did  not  affect  hepatic  uptake  of  IgA-IC  (31).  These  observations 
collectively suggest  that  a  glycosidic moiety of IgA-IC  is  not  involved in  the 
interaction of these immune complexes with the specific receptor on  Kupffer 
cells. 
The possibility was considered that the uptake of IgA-IC by Kupffer cells was 
mediated by complement receptors after the injected IgA-IC reacted with mouse 
complement  (32).  This  possibility,  however,  was  also  excluded  by  the  liver 
perfusion studies that showed hepatic uptake of IgA-IC in the absence of any 
serum proteins.  Furthermore, mouse IgA immune complexes were shown not 
to bind C3 or its components (33). 
Thus, these studies demonstrated the existence of specific receptors on Kupffer 
cells that  mediate the binding and clearance of IgA-IC in  mice. Saturation or 
dysfunction of similar receptors in  humans might contribute to  the increased 
serum levels and glomerular deposition of circulating, soluble IgA-IC reported 
in patients with IgA nephropathy, Sch6nlein-Henoch purpura, and glomerulo- 
nephritis associated with alcoholic liver cirrhosis. 
Summary 
To characterize the physiology of circulating IgA immune complexes (IgA- 
IC), the dynamics of IgA-IC removal by the liver were examined. After intrave- 
nous injection, covalently cross-linked IgA antibodies to the dinitrophenyl deter- 
minant were rapidly removed from the circulation by the liver. Immunofluores- 
cence microscopy and  light and electron microscope autoradiography showed 
that  the  IgA-IC were associated with  Kupffer cells.  With  increasing doses of 
injected IgA-IC the clearance velocity approached a maximum, thus prolonging 
the circulation of IgA-IC. All these observations indicated a  receptor-mediated 
process.  Saturating  doses  of various  potential  receptor-blocking agents,  heat- 
aggregated mouse IgG,  microaggregated human serum albumin, and purified 
dimeric  IgA  did  not  influence  the  clearance pattern  and  hepatic  uptake  of 
radiolabeled IgA-IC. Mouse livers were also perfused via the portal vein with  1 
ug of IgA-IC. In the presence or absence of serum proteins, 43% of the perfused 
IgA-IC were removed in a single passage. This liver uptake was not reduced with 
simultaneous perfusion  of large doses  of aggregated  mouse  IgG,  aggregated 
human serum albumin, or purified free dimeric mouse IgA. In contrast, the liver 
uptake of radiolabeled IgA-IC was decreased by 88% with the addition of 1 mg 
unlabeled IgA-IC.  These observations support  the conclusion that removal of 
IgA-IC from circulation is mediated by a specific IgA receptor on Kupffer cells. 
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